BTIG Sees Valeant's (VRX) Growth Plan Taking Longer than Expected to Implement; Affirms at 'Neutral' (WBA)

UPDATE: Valeant's (VRX) Plaque Psoriasis Injection Faces July 19th FDA Panel

(Updated - June 9, 2016 9:19 AM EDT)

Valeant Pharma's (NYSE: VRX) plaque psoriasis injection faces July 19th FDA panel, according to Bloomberg.

UPDATE - The HHS document is embedded below:

Valeant (VRX) PT Cut to $11 at Mizuho

Mizuho Securities analyst Irina Koffler reiterated an Underperform rating on Valeant Pharmaceuticals (NYSE: VRX) and cut her price target to $11.00 (from $18.00), saying she is not convinced of a turnaround.

Koffler commented, "Valeant lowered 2016 guidance for the second time this year.... More

Valeant (VRX) Said Near Agreement on Asset Sales - Source

Valeant (NYSE: VRX) is nearing an agreement to sell its Latin American operations, according to a source claiming to have knowledge of the situation. There is also a possibility Valeant could decide to divest Salix, the person said.

If the latter scenario is true and... More

Valeant Pharma (VRX) Said to Try Restructuring Walgreens (WBA) Pact - FT

(Updated)

Valeant Pharma (NYSE: VRX) is attempting to restructure its agreement with Walgreens (Nasdaq: WBA) after warning that it is losing money, according to the Financial Times. Valeant will consider terminating the agreement within months unless the situation improves, the report said.

Valeant Pharmaceuticals (VRX): Dermatology Is Losing Money - Jefferies

Jefferies analyst, David Steinberg, cut his PT on Valeant Pharmaceuticals (NYSE: VRX) to meet lowered guidance. Q1 revs exceeded consensus by ~$20M while EPS was $0.09 below consensus though both were within mgts guidance range. With a new CEO in place, VRX not surprisingly significantly... More

Valeant (VRX) PT Cut to $33 at RBC Capital

RBC Capital analyst Douglas Miehm lowered estimate and his price target on Sector Perform-rated Valeant Pharmaceuticals (NYSE: VRX) to $33.00 (from $58.00) following mixed earnings, which were overshadowed by sharply lower guidance.

Miehm commented, "Total revenue guidance was lowered to $9.9-10.1B, from $11.0-11.2B and cash EPS guidance... More

Valeant (VRX) PT Cut to $38 at BMO Capital

BMO Capital analyst Alex Arfaei reiterated a Market Perform rating and cut his price target on Valeant Pharmaceuticals (NYSE: VRX) to $38.00 (from $44.00) after the company cut guidance. While the firm expected the cut, it was greater than they and the market expected.

Arfaei commented, "Although we expected Valeant to lower its guidance, the magnitude of the downward revision was greater than we and the market expected. This... More